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Abstract Individuals <2 years and ≥50 years of age, as well
as those with other specific risk factors, are especially vulner-
able to invasive pneumococcal disease (IPD). Conjugate vac-
cines have been developed against encapsulated bacteria such
as Streptococcus pneumoniae to provide improved immune
responses. The 7-valent pneumococcal conjugate vaccine
(PCV7) has significantly reduced the burden of vaccine-type
pneumococcal diseases in children, including invasive disease
and pneumonia and acute otitis media. There have also been
significant declines in antimicrobial resistance in 7-valent
vaccine serotypes and carriage of S. pneumoniae in the post-
PCV7 era. Two to three years after the introduction of PCV13,
there is emerging, global evidence of a reduced burden of
pneumococcal diseases in children, including declines in IPD
(UK and Germany) and nasopharyngeal carriage of PCV13
serotypes (Portugal and France). The functional immunoge-
nicity of PCV13 in individuals ≥50 years of age has been
demonstrated in clinical trials in comparison with the 23-
valent pneumococcal polysaccharide vaccine and for children
and adults 6 to 49 years of age. Between 2011 and 2013,
PCV13 received market authorisation by the European Med-
icines Agency (EMA) for these additional age groups and is
now available in Europe for the prevention of pneumococcal
disease in all age groups.
Introduction: the burden of pneumococcal disease
The aim of this article is to discuss what could be expected
from 13-valent pneumococcal conjugate vaccine (PCV13) use
in the population over 5 years of age based current knowledge
from the post-marketing experience of childhood vaccination
with PCV13 and from pivotal trials performed in children,
adolescents and adults. We will also review the characteristics
of the immune response to conjugate vaccines.
The burden of invasive pneumococcal disease (IPD) is
high, especially in individuals <2 years and ≥65 years of age
who have the highest incidence and case fatality rate (CFR)
[1]. The overall incidence of IPD in Europe in 2010 was 5.2
cases per 100,000 population, with the most affected age
groups being <1 year and ≥65 years old (18.5 and 15.6 cases
per 100,000, respectively) [2]. In the USA, CFRs for IPD in
adults have not changed significantly over the last several
decades [3]. Mortality rates due to IPD have remained high
despite the availability of clear guidelines for treatment, with a
number of highly effective antibiotics [4].
The clinical presentation of IPD varies according to age.
Bacteraemia without source or focus of infection (i.e. non-
meningitis, non-pneumonia IPD) is the most common presen-
tation in children aged 0–5 years, with an estimated global
incidence of 87 cases per 100,000 versus 17 cases per 100,000
for pneumococcal meningitis [5]. In the Netherlands,
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pneumococcal pneumonia was the most frequent presentation
in adults during 2004–2006 [6]. Similar findings were ob-
served in a Spanish hospital-based surveillance study (the
ODIN study), in which pneumonia accounted for 70 % of
IPD cases in adults older than 18 years [7]. Within this study,
CFRs were also found to vary according to clinical presenta-
tion, with sepsis being associated with the highest rate (40 %),
followed by peritonitis (20 %) and complicated pneumonia
(18 %).
Certain comorbidities, including chronic heart, hepatic or
pulmonary disease, diabetes mellitus, acquired immunodefi-
ciency syndrome (AIDS) or other immunosuppressions, in-
crease the risk of pneumococcal diseases in both children and
adults [8]. A retrospective analysis of 22,000 IPD cases in
England (2002–2009) reported a higher risk of IPD-related
hospitalisation and mortality in individuals with comorbidities
versus those without comorbidities in all age groups. The
effect of underlying conditions on the risk of hospitalisation
for IPD was highest in children aged 2–15 years, with a nearly
12-fold increase in IPD in those with comorbidities compared
with those without (versus nearly 8-fold and 3-fold increases
in adults aged 16–64 years and adults aged ≥65 years,
respectively). Therefore, despite a significant reduction of
cases in populations in the post-PCV era, the risk of IPD is
generally still higher in comorbid versus healthy populations
and in immunocompromised versus immunocompetent pa-
tients. [9–12].
In addition to young and old age and certain comorbidities,
environmental, external and behavioural factors may predis-
pose individuals to pneumococcal diseases, as listed in Table 1
[13–15]. Torres et al. suggested that clinical presentations of
diseases are different according to the underlying conditions.
Pneumonia is common in patients with respiratory diseases
and/or in those who smoke, and bacteraemia is common in
cancer patients [7].
Pneumococcal pneumonia results in significant morbid-
ity, leading to high rates of hospitalisations, especially in
elderly patients. Hospitalisation rates due to pneumococcal
pneumonia in Spain were 0.25 per 1,000 in patients aged
50–54 years versus 4.21 per 1,000 in those ≥85 years of age
[16]. Streptococcus pneumoniae is the leading cause of
community-acquired pneumonia (CAP), accounting for
about 30 % of cases [17] and, thus, the epidemiology of
pneumococcal CAP can be extrapolated from all-cause
CAP. Torres et al. reported an increased risk of CAP in
men (compared with women), patients ≥65 years of age,
patients with certain comorbid conditions, such as previous
history of pneumonia, chronic respiratory disease, chronic
obstructive pulmonary disease or human immunodeficien-
cy virus (HIV) infection, and patients with specific lifestyle
factors, including being underweight, smoking, high alco-
hol consumption, regular contact with children in day care
or poor dental hygiene [18].
Key milestones in the development of pneumococcal
vaccines
Pneumococcal vaccines have been available for more than
100 years, starting with the development of the pneumococcal
whole-cell vaccine in 1911 [19], followed by the availability
of polysaccharide vaccines with increasing numbers of sero-
types, including the 23-valent pneumococcal polysaccharide
vaccine (PPV23), which became available in 1983. The 7-
valent pneumococcal conjugate vaccine (PCV7), which com-
prises pneumococcal polysaccharides for serotypes 4, 6B, 9V,
14, 18C, 19F and 23F, was introduced in 2000 in the USA and
in 2001 in Europe [20], and has been successfully used in
many childhood pneumococcal immunisation programmes
around the world. The World Health Organization (WHO)
has recently reported on the progress of PCV introductions
into national immunisation programmes (NIPs). As of De-
cember 2012, 44% ofWHOmember states had included PCV
in their routine infant immunisation schedule, representing
31 % of all children born in WHO member states [21]. In
2009, higher-valent PCVs became available. In Europe,
PCV10 (Synflorix®, comprising the additional serotypes: 1,
5 and 7F) was indicated for active immunisation against IPD
and acute otitis media (AOM) in infants and children from
6 weeks up to 5 years of age [22] and in 2013, the pneumonia
indication was added. In Europe, PCV13 (Prevenar 13®,
comprising the additional serotypes: 1, 3, 5, 6A, 7F and
19A) is indicated for the prevention of IPD, pneumonia and
AOM caused by S. pneumoniae in infants and children from
6 weeks up to the age of 17 years and for IPD in individuals
aged ≥18 years [23]. This reflects the expanded use of PCV13
in individuals ≥6 years of age in Europe. The marketing
authorisation for PCV13 for adults aged 50 years or over
was received in 2011.
Conjugate vaccines: what are their attributes?
Conjugate vaccines, comprising a conjugate between an anti-
genic protein and a polysaccharide, have been developed
against a variety of bacterial species, including S. pneumoniae,
Neisseria meningitidis and Haemophilus influenzae type b, to
overcome the issues associated with the T cell-independent
immunological characteristics of pure polysaccharide antigens
(reviewed by Blanchard-Rohner and Pollard [24]).
Apart from a few polysaccharides that carry both positive
and negative charges, most polysaccharides found in encap-
sulated bacteria and in polysaccharide vaccines cannot be
processed and bound to major histocompatibility complex
class II (MHC II) molecules for presentation to T-helper cells
and are, therefore, considered T-independent antigens [25,
26]. As a result, B-cell activation is incomplete and generally
occurs outside germinal centres. There is limited
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immunoglobulin (Ig) class switch (mostly IgM and IgG2) [27]
and somatic hypermutation (a process that is critical for
obtaining high-affinity antibodies) [28]. Most importantly,
the memory generated by exposure to such polysaccharides
is suboptimal compared with that observed after T-dependent
antigen stimulation and is mostly supported by long-lived
plasma cells [29] and short-lived memory B cells that differ
from T-dependent B cells [30].
B-cell response to pure polysaccharide vaccines is limited
to specific subsets, principally B1 cells and marginal zone B
cells [31]. B1 cells produce short-lived low-affinity antibody
responses that provide the first line of defence against patho-
gen invasion [24]. Marginal zone B cells are sensitive to
ageing and inflammation [32, 33]. Moreover, they are found
only in the spleen, which explains why the response to T-
independent antigens is limited after splenectomy [34]. Ac-
cordingly, increased rates of infections from encapsulated
bacteria in patients with asplenia or diminished splenic func-
tion have been attributed, in part, to the absence of marginal
zone B cells in these patients [24]. Infants <2 years of age are
also vulnerable to these infections as, before this age, the
marginal zone is immature and unable to support the devel-
opment of marginal zone B cells [35].
Repeated doses of polysaccharide vaccine administered at
intervals of <5 years have been shown to result in subsequent-
ly lower antibody levels (a phenomenon known as hypore-
sponsiveness) due to the depletion of polysaccharide-specific
B cells [36, 37]. It has been shown in a study in neonatal mice
receiving meningococcal serotype C polysaccharide booster
vaccine that this hyporesponsiveness is due to apoptosis of
memory B cells [38], possibly by the inhibition of critical
survival pathways for B cells [39].
In contrast with pure polysaccharide vaccines, conjugate
vaccines produce an immunological response involving both
B cells and T cells (Fig. 1). The chemical conjugation of a
carrier protein to the polysaccharide antigen results in activa-
tion of the B-cell receptor following polysaccharide binding.
The presentation of carrier protein peptides to the T cell in
association with MHC II on the B-cell surface also provides
signals for the activation of the T-helper cells [24]. This B
cell–T cell interaction, which normally takes place during
infections, provides the necessary costimulatory signals to B
cells to initiate the process of germinal centre reaction [24, 40,
41]. This results in high titres of opsonising antibodies with Ig
class switch and somatic hypermutation [24, 28]. New data for
conjugate vaccines against S. agalactiae (group B
Streptococcus) suggest that part of the carbohydrate molecule
also binds and subsequently activates T cells directed against
polysaccharide antigens [42]. In view of the crucial role of T
cells in mucosal immunity, this observation could help explain
the dramatic effect of conjugate vaccines in the reduction of
nasopharyngeal colonisation.
A conjugate vaccine, therefore, is expected to have benefits
over a polysaccharide vaccine, in terms of booster response,
immunological memory and generally improved immune re-
sponses, due to the T cell-dependent characteristics of the
immune response.
PCV immunisation in infants: what have we learnt so far?
PCV7 has significantly reduced the burden of pneumococcal
diseases in children. PCV7 was introduced in the USA in
2000. The Centers for Disease Control and Prevention
(CDC) reported a 77 % reduction in overall IPD rates and a
98 % reduction in PCV7 serotype disease in children aged
<5 years for 2005 compared with pre-PCV7 years (1998–
1999), based on an analysis of laboratory and population
surveillance data [43]. Reductions in overall and/or PCV7
serotype IPD cases have also been documented in children
aged <2 or <5 years in many other countries, including Aus-
tralia, Canada, France, Norway and Spain, following the
introduction of PCV7 [44–49]. Furthermore, reductions in
hospitalisation rates for all-cause pneumonia (39 %) and
pneumococcal pneumonia (65 %) in children <2 years of
age have been observed in an US analysis of admissions data
Table 1 Factors associated with an increased risk of pneumococcal diseases


















Functional and anatomical asplenia
Socioeconomic
Environmental
• Preceding viral respiratory infection
• Residence in an institution
(e.g. nursing home)
• Frequent contact with children
Smoking
Heavy alcohol use
CCVD: cardiovascular and cerebrovascular disease; CPD: chronic pulmonary disease, CLD: chronic liver disease; CRF: chronic renal failure; HIV:
human immunodeficiency virus
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[50]. Similarly, a Polish study found that pneumonia admis-
sion rates significantly declined following the introduction of
PCV7 in children <5 years of age in the city of Kielce [51].
PCV7 has also reduced otitis media in children aged <2 years,
as demonstrated by a ≥28% reduction in recurrent otitis media
[52] and a ≥43 % reduction in AOM outpatient visits or
prescriptions [53].
Antibiotic resistance in vaccine serotypes and carriage of
S. pneumoniae has declined since the introduction of PCV7.
Kyaw et al. reported an 81 % decrease in penicillin-resistant
IPD (almost all caused by vaccine or vaccine-related sero-
types) among children aged <2 years in the USA [54]. In
addition, reductions in the carriage of vaccine serotypes and
antibiotic-resistant serotypes have been observed in Greece
and the USA [55, 56].
PCV7 has demonstrated an indirect effect in unvaccinated
populations (herd effect), as exemplified by declines in IPD
cases within adults aged ≥65 years and infants ≤60 days of age
in Canada and the USA [10, 45]. A review of data from 14
countries, most of which were developed countries, also re-
ported consistent and significant declines in both vaccine-type
IPD and vaccine-type pneumococcal carriage following PCV
introduction in individuals not targeted for PCV vaccination
[57]. These decreases were found to be contemporaneous in
studies assessing both vaccine-type carriage and vaccine-type
IPD, and longitudinal data demonstrated continued declines,
with the greatest declines occurring in the first few years
following PCV introduction.
Since the availability of PCV7 in 2000/2001, there have
been changes in the overall serotype distribution of
S. pneumoniae, in particular, a rise in serotype 19A has been
observed globally. The estimated proportion of IPD caused by
serotype 19A has ranged from 22 % reported in a Spanish
study (2001–2005) in 85 vaccinated and unvaccinated indi-
viduals <5 years of age to 40 % in a US study (2005) in 1.26
million individuals <5 years of age [43, 58]. A rate of 27 %
has also been reported in cases of pneumococcal pneumonia
in a French study [59]. This changing serotype epidemiology
has led to the development and introduction of higher-valent
pneumococcal conjugate vaccines, including PCV13, which
includes serotype 19A, to provide improved serotype cover-













































Fig. 1 Immune response to
polysaccharide and conjugate
vaccines. a Polysaccharides from
the encapsulated bacteria that
cause disease in early childhood
stimulate B cells by cross linking
the B cell receptor (BCR) and
drive the production of
immunoglobulins. This process
results in a lack of production of
new memory B cells and a
depletion of the memory B cell
pool, such that subsequent
immune responses are decreased.
b The carrier protein from
protein–polysaccharide conjugate
vaccines is processed by the
polysaccharide specific B cell,
and peptides are presented to
carrier peptide specific T cells,
resulting in T cell help for the
production of both plasma cells
and memory B cells. CD40L,
CD40 ligand; TCR, T cell
receptor. Reprinted with
permission from Macmillan
Publishers Ltd.: Pollard et al. Nat
Rev Immunol 2009;9(3):213–20
[37], copyright 2009
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By 2013, 2–3 years after the widespread use of PCV13,
there were emerging data concerning the impact of PCV13
on the rate of vaccine serotype-specific IPD in children.
There has been a decline in IPD in the UK, due to the six
additional serotypes in PCV13 following the introduction
of PCV13 in April 2010 (Fig. 2) and a sustained decline in
IPD due to shared serotypes in PCV7 and PCV13 [60].
Furthermore, reductions in IPD due to PCV13 serotypes
have been reported in children <2 years of age in Germany
following the introduction of PCV10 and PCV13 [61].
Temporal trends in nasopharyngeal carriage have also been
monitored in several studies following the introduction of
PCV13. In a study of 448 healthy children aged ≤6 years
attending day-care centres in Portugal, there were reduc-
tions of 8 % and 10 %, respectively, in the incidence of
nasopharyngeal carriage of serotypes 19A and 6C from
2010 to 2011 following the introduction of PCV13 [62].
Similarly, in a French study involving children <2 years of
age with AOM, significant reductions in the nasopharyn-
geal carriage of PCV13 serotypes were found in PCV13-
vaccinated children (n=652) compared with PCV13-
unvaccinated individuals (n=290) within 1 year of PCV13
introduction (p<0.001) [63]. This reduction in nasopharyn-
geal carriage is important for the control of pneumococcal
diseases in adults, as children in day care are a key source
of transmission to adults, as demonstrated by a US case–
control study, which found this to be an independent risk
factor for IPD in adults (odds ratio 3.0; 95 % confidence
interval [CI] 1.5–6.2; p=0.003) [64].
Similar to the PCV7 experience, in countries where there
has been a high uptake of PCV13 within childhood
immunisation programmes, there has been a decline in
vaccine-type IPD cases in adults, indicating a possible early
herd effect. For example, in Norway, which had a vaccine
coverage rate of 92 % for children <2 years of age in 2012,
IPD cases caused by PCV13 serotypes in individuals
≥65 years old declined from 27/100,000 in 2010 to 18/
100,000 in 2012 [65, 66]. There have also been declines in
the number of IPD cases caused by the additional PCV13
serotypes (1, 3, 5, 6A, 7F and 19A) in individuals aged
≥5 years in the UK and in adults in Germany since the
introduction of paediatric PCV13 vaccination [60, 67]. These
data have led to a debate about whether there will be a reduced
requirement for adult vaccination as the indirect effect of
PCV13 increases. However, despite this potential herd effect,
a significant burden of pneumococcal disease in adults re-
mains and direct vaccination of adults is the optimal way to
provide individual protection to those at risk and to signifi-
cantly reduce the pneumococcal disease burden in the adult
population.
There is also evidence that PCV10 has reduced the
burden of pneumococcal diseases in children. Palmu
et al. reported point estimates for PCV10 efficacy against
vaccine-type IPD of 100 (95 % CI 83–100) for the 3+1
schedule and 92 (58–100) for the 2+1 schedule in a
cluster-randomised, double-blind trial, involving Finnish
children aged <19 months, vaccinated with PCV10 or
hepatitis vaccines (control group) [68]. A PCV10 study
in Canada has shown some evidence of reduced vaccine-
type IPD in infants, with a reduction in IPD cases caused
by the additional three PCV10 serotypes (1, 5 and 7F)
observed following the introduction of PCV10 [69]. A
reduction in hospitalisation rates due to pneumonia has
also been reported in Brazil 1 year after the introduction
of PCV10 into the NIP [70]. No available data as of July
2014 have been reported on the impact of PCV10 in non-
vaccine eligible populations. PCV10 has been shown to be
immunogenic in a number of primary and booster vacci-
nation studies [71–75], and also to reduce vaccine-type
pneumococcal carriage [76].
PCV immunisation in other age groups
In Europe, PCV13 was licensed for use in individuals aged 6–
49 years and for adults aged ≥50 years in 2011 [23]. Prior to
this, PPV23 was the only pneumococcal vaccine licensed for
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Fig. 2 Rates of invasive
pneumococcal disease (IPD)
caused by six additional serotypes
in PCV13* among children aged
<2 years (2006–2013).
*Serotypes 1, 3, 5, 6A, 7F and
19A. Reprinted with permission
from Public Health England [60].
PCV13, 13-valent pneumococcal
conjugate vaccine
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serotypes in adults in whom there is an increased risk of
morbidity and mortality from pneumococcal diseases [77].
However, although PPV23 has been shown to reduce IPD
in adults, data concerning the prevention of pneumococcal
pneumonia or mortality are less clear [78]. Also, some
limitations have been observed with this vaccine in im-
munodeficient patients, possibly associated with poor or
absent immunogenicity [79]. In a randomised, placebo-
controlled study (n=1,392) conducted in Uganda, PPV23
was found to be ineffective in preventing a first episode of
IPD in individuals with HIV (hazard ratio [HR] 1.47;
95 % CI 0.7–3.3) [80]. In contrast, in a more recent study
conducted in Malawi, PCV7 was found to be effective in
preventing vaccine-serotype IPD in individuals with HIV
(n=439) when compared with placebo (HR 0.26; 95 % CI
0.1–0.7) [81].
The immunogenicity and safety of PCV13 has been
demonstrated in a clinical programme that supported
licensure. This programme was designed to evaluate
the functional immune response to PCV13 compared
with PPV23 in two patient populations: adults 60–64
years of age who were naïve to PPV23 and those aged
≥70 years immunised with PPV23 at least 5 years be-
fore study enrolment [82, 83]. In both these populations,
primary vaccination with PCV13 resulted in significant-
ly higher anti-pneumococcal functional antibody re-
sponses (as assessed by opsonophagocytic activity
[OPA] titres 1 month post-vaccination) than PPV23 for
the majority of the PCV13 serotypes [82, 83]. Further-
more, unlike PPV23, PCV13 did not negatively affect
the responses to a second dose of PCV13 administered
1 year later in the PPV23-preimmunised individuals
aged ≥70 years [83]. An extension study conducted in
the previously PPV23-naïve individuals also demonstrat-
ed that primary PCV13 vaccination can produce an
immunological state, which allows recall anti-
pneumococcal responses to subsequent vaccination with
either PCV13 or PPV23. In contrast, primary PPV23
vaccination resulted in an immune state in which a
subsequent PPV23 dose generally yielded inferior re-
sponses compared with the initial response [84]. In an
analysis from three PCV13 clinical studies, the function-
al immune response to PCV13 in high-risk individuals
with chronic medical conditions (diabetes mellitus or
stable, chronic cardiovascular, pulmonary, liver or renal
disease) was similar to that in non-high-risk individuals
within these trials [85].
The immunogenicity of PCV13 has also been demon-
strated in individuals aged 5–17 years. The immune
response to PCV13 (as assessed by anti-pneumococcal
IgG geometric mean concentrations) was shown to be
non-inferior in children aged 5 to <10 years previously
vaccinated with PCV7 compared with a PCV7/PCV13
post-toddler dose from a historical control study. The
functional immunogenicity of PCV13 was also demon-
strated to be non-inferior in PCV7-naïve children aged
10–17 years compared with that in those aged 5 to
<10 years [86]. A similar bridging study was also con-
ducted in the age group 18–49 years.
What can we expect from pneumococcal vaccination?
According to the WHO data, PCVs are used in 87 NIPs
worldwide [21]. Within Western Europe, the use of specific
PCVs in NIPs varies according to country (Fig. 3). In addi-
tion, national vaccination recommendations outside routine
infant immunisation programmes differ among EU coun-
tries (Table 2). Some countries have age-based vaccination
programmes, while others have risk-based programmes,
and some countries have regional variations with respect
to recommendations. There are also differences between
scientific society guidelines. For example, in France and
Spain, the French National Reference Center of Primary
Immunodeficiencies (CEREDIH) [100] and the Spanish
Society of Preventive Medicine, Public Health and Hygiene
(SEMPSPH) [101], respectively, recommend PCV13 for
immunocompromised patients. PCV13 is also recom-
mended for renal failure and dialysis, and for smokers
in Spain (SEMPSPH and Smoking Working Group of the
Spanish Pulmonologist Society [SEPAR] recommenda-
tions, respectively) [101, 102]. In Germany, the Robert
Koch Institute (RKI) and German Society for Hematolo-
gy and Oncology (DGHO) guidelines recommend
PCV13 followed by vaccination with PPV23 for asplenic
patients [103, 104]. Within Italy, PCV13 is recommended
in individuals of all ages within the ‘Vaccination calen-
dar for life’ approved by the main public health, paedi-
atric and general practitioner organisations [105]. These
guidelines, however, may evolve as clinical experience
with PCV13 increases, especially in relation to the more
recent indications (adults ≥18 years of age and children/
adolescents aged 6–17 years).
The WHO has published guidance for the introduc-
tion of new vaccines [106]. Cost-effectiveness, as well
as disease burden, efficacy, safety and quality are rec-
ommended as key elements that should be considered as
part of this process. In Italy, the clinical and economic
impact of an adult pneumococcal vaccination pro-
gramme has been assessed using an ad hoc population
model and paediatric efficacy data [107]. This analysis
found that, as a consequence of avoided pneumococcal
infections, age-based PCV13 immunisation in elderly
individuals (aged ≥65 years) resulted in savings ranging
from 7 to 19 million Euros, depending on the vaccina-
tion strategy. An adult pneumococcal vaccination
Eur J Clin Microbiol Infect Dis
programme was, therefore, considered to be cost-
effective from the payer perspective. Similarly, a Ger-
man cost-effectiveness analysis, which also utilised pae-
diatric data, indicated that adult PCV13 vaccination
would provide substantial health and economic benefits
relative to PPV23 or no vaccination [108]. However,
these findings will need to be verified with adult effi-
cacy data, when available. The efficacy of PCV13 in
the prevention of a first episode of vaccine-serotype-
specific pneumococcal CAP was studied in the
Community-Acquired Pneumonia Immunization Trial in
Adults (CAPiTA) [109] that was recently completed.
This randomised placebo-controlled trial [110] involved
a pneumococcal vaccination-naïve population of 85,000
community-dwelling adults ≥65 years of age from the
Netherlands.
Given both data from clinical trials and our experi-
ence of paediatric PCV13 vaccination, a beneficial ef-
fect could be expected with adult vaccination. A global
literature review demonstrated reductions in vaccine-
type and all-type IPD in vaccine-eligible children as
well as age groups that were not eligible for vaccination
following PCV7 introduction [111]. Within the 18 stud-
ies assessing the impact of PCV7 in vaccine-eligible
children in the post-vaccination period, the median rate
of reductions in vaccine-type IPD incidence was 90.1 %
(range 39.9–99.1 %). Another literature review reported
reductions in hospitalisation rates associated with pneu-
mococcal pneumonia, ranging from 57 to 71 %, in
children aged <2 years, as well as a reduction in mor-
tality associated with all-type IPD in children [112].
There is also emerging, global evidence of a reduced
burden of pneumococcal diseases (IPD, AOM and men-
ingitis) in children following the introduction of PCV13.
In addition to reductions in IPD cases within the UK
and Germany (mentioned above), there have also been
reports of reductions in the incidence of vaccine-type
IPD in the USA and Spain [113, 114], as well as
reductions in meningitis cases in Greece [115] and
vaccine-type AOM cases in the USA and Spain [116,
117].
Conclusion
Given the high burden of pneumococcal diseases, pneumo-
coccal vaccination is a key element of global disease preven-
tion. Conjugate vaccines elicit a qualitatively and quantitative-
ly higher level of immune response than polysaccharide vac-
cines, and, thus, provide greater immunity in children <2 years
of age and in those with compromised immunity than polysac-
charide vaccines. 13-valent pneumococcal conjugate vaccine
PCV13
PCV13 only:
Belgium, Denmark, France, Ireland, Italy,
Norway, Switzerland, United Kingdom
     
PCV10 only:  
Austria, Cyprus, Finland, Netherlands 
     
PCV13/PCV10: 
















Fig. 3 Pneumococcal conjugate
vaccine usage in national
childhood immunisation
programmes in Western Europe.
PCV10, 10-valent pneumococcal
conjugate vaccine; PCV13, 13-
valent pneumococcal conjugate
vaccine
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Table 2 National adult pneumococcal vaccination recommendations in Western Europe
Country (year)a Vaccine Pneumococcal vaccine recommendation
Age
based





≥50 years High-risk group (≥6 years): asplenia (anatomical, functional); chronic renal insufficiency; cochlear implant;
complement and properdin deficiency; haematopoietic organ disorder; HIV; hypogammaglobulinaemia;
immunodeficiency (congenital, acquired); liquor fistula; nephritic syndrome; nephrotic syndrome prior to
immunosuppressive therapy; neurological disorder (in children); sickle cell anaemia; transplantation
(organ, subsequent to stem cell transplantation)
At-risk group (≥6 years): chronic cardiovascular disease (except hypertension); chronic respiratory disease;





≥65 years High-risk groups (≥18 years): asplenia; autoimmune disease/immune-mediated inflammatory disease;
cochlear implant; haematological cancer; HIV; immunodeficiency; organ transplantation
Risk groups (≥50 years): alcoholism; chronic disease (heart, kidney, liver, respiratory); smoking
Denmark (2012)
[89]
PCV13 ≥65 years At-risk group (any age): asplenia (functional); cochlear implant; CSF leak; HIV; history of IPD; lymphoma;
organ transplantation; splenectomy (completed/planned)
At-risk group (18–65 years): chronic disease (heart, kidney, liver, lung); diabetes mellitus
Finland (2013)
[90]
PCV13 No High risk (≥5 years): asplenia (functional, anatomical); cochlear implant; HIV; immunodeficiency
(congenital, acquired); liquor fistula; lymphoma; multiple myeloma; nephrotic syndrome; patients treated
with systemic corticosteroids or other immunosuppressants; transplantation (organ, tissue)
PPV23 ≥65 years At risk or in permanent institutional care (≥5 years): chronic disease (cardiac, pulmonary); diabetes (type 1);
hepatic insufficiency; patients treated with systemic corticosteroids or other immunosuppressants; renal
insufficiency; transplantation (organ, tissue)
France (2013)
[91]
PCV13 No At-risk group (≥2 years): asplenia or hyposplenia; cancer treated by chemotherapy (solid tumour,
haematological); cochlear implant or planned cochlear implant; HIV; immunodeficiency (congenital);
immunosuppressive therapy, biotherapy, or corticotherapy for autoimmune disease or chronic
inflammation; meningeal fistula; nephrotic syndrome; transplantation or waiting for transplantation
(organ, haematopoietic stem cell)
PPV23 No At-risk group (≥5 years): asthma (severe with continuous treatment); chronic liver disease (alcoholic or non-
alcoholic origin); chronic respiratory failure; COPD; cyanotic congenital heart disease; diabetes (not
balanced by diet); emphysema; heart failure; kidney failure
Germany (2013)
[92]
PCV13 ≥60 years At-risk group (≥2 years): asplenia; autoimmune disease; chronic disease (heart, kidney, respiratory); CSF





PPV23 ≥60 years At-risk group (≥5 years): asplenia; autoimmune disease; cancer (haematological, solid tumour); chronic
disease (heart, kidney, liver, respiratory); CNS disease; CSF leak; HIV; immunodeficiency (congenital,
acquired); metabolic disease; transplantation (organ)
Greece (2011)
[93]
PCV13 >50 years No
Ireland (2013)
[94]
PPV23 ≥65 years High-risk group (18–64 years): asplenia, hyposplenia (including splenectomy, sickle cell disease,
haemoglobinopathies and coeliac disease); cochlear implant (candidates, recipients); complement
deficiency (particularly C1–C4); CSF leak (congenital, complicating skull fracture, neurosurgery);
immunosuppressive conditions (e.g. some B- and T-cell disorders, HIV infection, leukaemia, lymphoma)
and those receiving immunosuppressive therapies; intracranial shunt; post-haematopoietic stem cell
transplant; solid organ transplant
At-risk group (18–64 years): chronic heart, lung or liver disease; chronic renal disease or nephrotic
syndrome; diabetes mellitus requiring insulin or oral hypoglycaemic drugs; individuals with occupational
exposure to metal fumes (i.e. welders)
Luxembourg
(2008) [95]
PPV23 >60 years At risk or in permanent institutional care (≥18 years): alcoholism; asplenia; chronic disease (cardiovascular,
renal, respiratory); cochlear implant; CSF leak; diabetes; HIV; liquor fistula; liver cirrhosis; lymphoma;
multiple myeloma; nephrotic syndrome; sickle cell disease; transplantation (organ)
Norway (2013)
[96, 97]
PCV13 No At-risk groups (all ages): asplenia; HIV; stem cell transplantation
Also, considered for following groups after collective evaluation of risk: B-cell deficiency; cancer
(haematological); cochlear implant; CSF leak; transplantation (organ)
PPV23 ≥65 years At-risk groups (all ages): asplenia; B-cell deficiency; cancer (haematological); cochlear implant; CSF leak;
HIV; transplantation (organ, bone marrow)
Sweden
(1994) [98]
PPV23 ≥65 years At-risk group (≥2 years): agammaglobulinaemia; alcoholism; asplenia; asthma; autoimmune disease;
cancer (haematological, solid tumour); chronic disease (heart, kidney, liver, respiratory); cyanotic heart
disease; CNS disease; CSF leak; haemodynamically significant residual lesion after surgery;
Eur J Clin Microbiol Infect Dis
(PCV13) expectations in the more recently indicated popula-
tions (adults aged ≥50 years and children and adolescents) can
be built on the heritage of PCV7 effectiveness data in children,
as well as emerging impact data for PCV13. The Community-
Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
trial should provide more definitive data on the role of adult
PCV13 vaccination in preventing vaccine-serotype-specific
pneumococcal community-acquired pneumonia (CAP). Con-
tinued surveillance will be important to determine the impact
of PCV13 on pneumococcal diseases in these age groups and
also to monitor the evolution of causative serotypes.
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